Dirceu Barbano reappointed head of Brazil's Anvisa
This article was originally published in SRA
Executive Summary
Dirceu Barbano has been reappointed director of Brazilian healthcare products regulatory agency Anvisa for a second three-year term. The priorities for Anvisa during Mr Barbano’s tenure will be to make the agency "more efficient without compromising on the rigour that characterises its decision-making". This will be achieved by "improving the regulatory framework [and through] closer dialogue with society", Mr Barbano told the Senate's Social Affairs Commission (CAS), which gave final approval to the appointment. Mr Barbano, a pharmacist, joined Anvisa in October 2008 and has been serving as the agency's director-president since January 2011.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.